Spatial Domain (Tier 1)
301-350 of 2,070
Download spatial tables
Spatial Domain (Tier 1)
Dominant neighborhood compartment and purity from Tier 1 domain summaries.
2,069 ready
| Sample | Organ | Disease state | Cells | Dominant compartment ?Largest Tier 1 spatial domain by sample fraction; this is a biological neighborhood label, not a row-count summary. | Domain share | Purity | Diversity |
|---|---|---|---|---|---|---|---|
| NSCLC_38242124__IMC__175_C3,10 | Lung | Primary cancer | 4,126 | Tumor/Malignant | 38.2% | 0.97 | 0.15 |
| NSCLC_38242124__IMC__175_C3,11 | Lung | Primary cancer | 3,559 | Tumor/Malignant | 37.8% | 0.99 | 0.05 |
| NSCLC_38242124__IMC__175_C3,12 | Lung | Primary cancer | 5,911 | Stromal | 71.6% | 0.95 | 0.15 |
| NSCLC_38242124__IMC__175_C3,13 | Lung | Primary cancer | 4,207 | Stromal | 60.4% | 0.94 | 0.16 |
| NSCLC_38242124__IMC__175_C3,14 | Lung | Primary cancer | 3,826 | Stromal | 61.8% | 0.91 | 0.25 |
| NSCLC_38242124__IMC__175_C3,15 | Lung | Primary cancer | 283 | Stromal | 58.0% | 0.85 | 0.37 |
| NSCLC_38242124__IMC__175_C3,16 | Lung | Primary cancer | 5,848 | Immune | 61.0% | 0.99 | 0.05 |
| NSCLC_38242124__IMC__175_C3,2 | Lung | Primary cancer | 2,343 | Tumor/Malignant | 34.0% | 0.67 | 0.62 |
| NSCLC_38242124__IMC__175_C3,3 | Lung | Primary cancer | 3,110 | Stromal | 22.5% | 0.81 | 0.46 |
| NSCLC_38242124__IMC__175_C3,4 | Lung | Primary cancer | 3,721 | Tumor/Malignant | 47.8% | 0.92 | 0.26 |
| NSCLC_38242124__IMC__175_C3,5 | Lung | Primary cancer | 2,899 | Tumor/Malignant | 45.2% | 0.94 | 0.21 |
| NSCLC_38242124__IMC__175_C3,6 | Lung | Primary cancer | 2,613 | Stromal | 30.5% | 0.59 | 0.79 |
| NSCLC_38242124__IMC__175_C3,7 | Lung | Primary cancer | 3,382 | Tumor/Malignant | 45.0% | 0.93 | 0.25 |
| NSCLC_38242124__IMC__175_C3,8 | Lung | Primary cancer | 2,698 | Tumor/Malignant | 62.9% | 0.95 | 0.16 |
| NSCLC_38242124__IMC__175_C3,9 | Lung | Primary cancer | 2,511 | Tumor/Malignant | 47.1% | 0.97 | 0.12 |
| NSCLC_38242124__IMC__175_C4,1 | Lung | Primary cancer | 1,967 | Tumor/Malignant | 62.4% | 0.96 | 0.14 |
| NSCLC_38242124__IMC__175_C4,10 | Lung | Primary cancer | 3,736 | Tumor/Malignant | 50.4% | 0.99 | 0.07 |
| NSCLC_38242124__IMC__175_C4,11 | Lung | Primary cancer | 3,999 | Tumor/Malignant | 37.4% | 0.95 | 0.18 |
| NSCLC_38242124__IMC__175_C4,12 | Lung | Primary cancer | 5,572 | Stromal | 79.9% | 0.98 | 0.06 |
| NSCLC_38242124__IMC__175_C4,13 | Lung | Primary cancer | 4,073 | Stromal | 75.2% | 0.98 | 0.07 |
| NSCLC_38242124__IMC__175_C4,14 | Lung | Primary cancer | 3,144 | Stromal | 69.9% | 0.99 | 0.07 |
| NSCLC_38242124__IMC__175_C4,15 | Lung | Primary cancer | 249 | Stromal | 59.0% | 0.52 | 0.78 |
| NSCLC_38242124__IMC__175_C4,16 | Lung | Primary cancer | 6,459 | Immune | 65.6% | 0.98 | 0.07 |
| NSCLC_38242124__IMC__175_C4,2 | Lung | Primary cancer | 680 | Tumor/Malignant | 42.1% | 0.86 | 0.39 |
| NSCLC_38242124__IMC__175_C4,3 | Lung | Primary cancer | 3,662 | Stromal | 30.0% | 0.55 | 0.89 |
| NSCLC_38242124__IMC__175_C4,4 | Lung | Primary cancer | 4,287 | Tumor/Malignant | 44.3% | 0.96 | 0.15 |
| NSCLC_38242124__IMC__175_C4,5 | Lung | Primary cancer | 3,460 | Tumor/Malignant | 33.8% | 0.95 | 0.19 |
| NSCLC_38242124__IMC__175_C4,6 | Lung | Primary cancer | 2,738 | Stromal | 39.4% | 0.81 | 0.50 |
| NSCLC_38242124__IMC__175_C4,7 | Lung | Primary cancer | 3,332 | Tumor/Malignant | 52.8% | 0.98 | 0.10 |
| NSCLC_38242124__IMC__175_C4,8 | Lung | Primary cancer | 2,762 | Tumor/Malignant | 69.9% | 0.90 | 0.26 |
| NSCLC_38242124__IMC__175_C4,9 | Lung | Primary cancer | 2,185 | Stromal | 27.6% | 0.80 | 0.60 |
| NSCLC_38242124__IMC__175_C5,1 | Lung | Primary cancer | 2,668 | Tumor/Malignant | 34.0% | 0.90 | 0.35 |
| NSCLC_38242124__IMC__175_C5,10 | Lung | Primary cancer | 1,820 | Tumor/Malignant | 37.6% | 0.96 | 0.16 |
| NSCLC_38242124__IMC__175_C5,11 | Lung | Primary cancer | 3,674 | Stromal | 44.9% | 0.75 | 0.57 |
| NSCLC_38242124__IMC__175_C5,12 | Lung | Primary cancer | 4,098 | Tumor/Malignant | 61.3% | 0.97 | 0.15 |
| NSCLC_38242124__IMC__175_C5,13 | Lung | Primary cancer | 4,056 | Tumor/Malignant | 42.9% | 0.75 | 0.56 |
| NSCLC_38242124__IMC__175_C5,14 | Lung | Primary cancer | 3,531 | Tumor/Malignant | 28.5% | 0.96 | 0.21 |
| NSCLC_38242124__IMC__175_C5,15 | Lung | Primary cancer | 1,378 | Other | 28.0% | 0.64 | 0.58 |
| NSCLC_38242124__IMC__175_C5,16 | Lung | Primary cancer | 5,027 | Immune | 73.6% | 0.99 | 0.04 |
| NSCLC_38242124__IMC__175_C5,2 | Lung | Primary cancer | 4,032 | Tumor/Malignant | 88.5% | 0.98 | 0.07 |
| NSCLC_38242124__IMC__175_C5,3 | Lung | Primary cancer | 3,017 | Tumor/Malignant | 54.6% | 0.94 | 0.19 |
| NSCLC_38242124__IMC__175_C5,4 | Lung | Primary cancer | 2,980 | Stromal | 25.8% | 0.76 | 0.55 |
| NSCLC_38242124__IMC__175_C5,5 | Lung | Primary cancer | 2,204 | Tumor/Malignant | 56.9% | 0.95 | 0.17 |
| NSCLC_38242124__IMC__175_C5,6 | Lung | Primary cancer | 4,848 | Tumor/Malignant | 77.6% | 0.98 | 0.08 |
| NSCLC_38242124__IMC__175_C5,7 | Lung | Primary cancer | 3,338 | Stromal | 46.1% | 0.89 | 0.36 |
| NSCLC_38242124__IMC__175_C5,8 | Lung | Primary cancer | 2,441 | Tumor/Malignant | 80.4% | 0.97 | 0.09 |
| NSCLC_38242124__IMC__175_C5,9 | Lung | Primary cancer | 1,960 | Immune | 33.2% | 0.92 | 0.28 |
| NSCLC_38242124__IMC__175_C6,1 | Lung | Primary cancer | 2,335 | Tumor/Malignant | 33.2% | 0.92 | 0.27 |
| NSCLC_38242124__IMC__175_C6,10 | Lung | Primary cancer | 2,263 | Stromal | 41.7% | 0.86 | 0.36 |
| NSCLC_38242124__IMC__175_C6,11 | Lung | Primary cancer | 6,002 | Stromal | 67.2% | 0.99 | 0.04 |